Recent Company News

• 04:38 AM ET Oct 01, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 01:13 AM ET Feb 03, 2026
  

  Addex Therapeutics announces publication of data in Molecular Psychiatry demonstrating that targeting mGlu7 with negative allosteric modulators could be transformative in treatment of anxiety and fear-related disorders (CHF 0.05, 0.00)

• 01:04 AM ET Jan 07, 2026
  

  Addex Therapeutics announces Neurosterix starts a Phase 1 clinical study with NTX-253 for Schizophrenia (CHF 0.05, 0.00)

• 04:03 PM ET Dec 10, 2025
  

  Addex Therapeutics enters ATM offering agreement for up to 3.3M ADSs - 424B5 (CHF 0.05, 0.00)

• 01:11 AM ET Dec 04, 2025
  

  Addex Therapeutics reports Q3 net income (CHF1.6M) vs year-ago (CHF1.5M) (CHF 0.06, 0.00)

• 04:02 PM ET Nov 19, 2025
  

  Addex Therapeutics files $150M equity shelf - F-3 (CHF 0.06, 0.00)